10 Economics of osteoarthritis: a global perspective

https://doi.org/10.1016/S0950-3579(97)80011-8Get rights and content

Musculoskeletal disorders, of which osteoarthritis (OA) is the most common, incur significant economic, social and psychological costs. Costs of illness have risen over recent decades accounting for up to 1–2.5% of the gross national product for those countries studied so far, including the USA, Canada, the UK, France and Australia. Arthritis has a significant impact on psychosocial and physical function and is known to be the leading cause of disability in later life. There are also significant out-of-pocket costs and loss of earnings due to changes in occupation and roles in domestic duties. Current guidelines for the management of OA of hip and knee include the recommendation of inexpensive but effective interventions. Although the guidelines have not had a specific economic evaluation, cost reductions may be expected. OA is a very common disease and will become an increasing economic burden as the population ages.

References (65)

  • Australian Bureau of Statistics

    National Health Survey: musculoskeletal conditions

  • BachmeierC

    Management of osteoarthritis in general practice: evaluation of an educational program (Master treatise)

    (1997)
  • BadleyEM

    The impact of musculoskeletal disorders on the Canadian population

    Journal of Rheumatology

    (1992)
  • BadleyEM

    The economic burden of musculoskeletal disorders in Canada is similar to that of cancer, and may even be higher

    Journal of Rheumatology

    (1995)
  • BadleyEM et al.

    Impact of disablement due to rheumatic disorders in a British population: estimates of severity and prevalence from the Calderdale Rheumatic Disablement Survey

    Annals of the Rheumatic Disease

    (1993)
  • BadleyEM et al.

    Disablement associated with rheumatic disorders in a British population: problems with activities of daily living and level of support

    British Journal of Rheumatology

    (1993)
  • BadleyEM et al.

    An international comparison of the estimated effect of the aging of the population on the major cause of disablement, musculoskeletal disorders

    Journal of Rheumatology

    (1995)
  • BadleyEM et al.

    Relative importance of musculoskeletal disorders as a cause of chronic health problems, disability and health care utilization: Findings from the 1990 Ontario Health Survey

    Journal of Rheumatology

    (1994)
  • BrooksP et al.

    The economic impact of joint replacement surgery: a preliminary analysis

  • BurkhauserR et al.

    Effects of arthritis on wage earnings

    Journal of Gerontology

    (1986)
  • ChangRW et al.

    A cost-effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip

    Journal of the American Medical Association

    (1996)
  • CornelissenP et al.

    The arthritis sufferer and the community: a comparison of arthritis sufferers in rural and urban areas

    Annals of the Rheumatic Diseases

    (1988)
  • CushnaghanJ et al.

    Taping the patella medially: a new treatment for osteoarthritis of the knee joint?

    British Medical Journal

    (1994)
  • DieppeP et al.

    A two year, placebo-controlled trial of non-steroidal anti-inflammatory therapy in osteoarthritis of the knee joint

    British Journal of Rheumatology

    (1993)
  • EberhardtK et al.

    Early rheumatoid arthritis: some social, economic and psychological aspects

    Scandinavian Journal of Rheumatology

    (1993)
  • EttingerWH et al.

    A randomised trial comparing aerobic exercise and resistance exercise with a health education program in older adults with knee osteoarthritis

    Journal of the American Medical Association

    (1997)
  • FeltsW et al.

    The economic impact of the rheumatic diseases in the United States

    Journal of Rheumatology

    (1989)
  • FreedmanD

    Arthritis: the painful challenge

    Searle Social Research Fellowship Report

    (1989)
  • GabrielSE et al.

    Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis

    Annals of Internal Medicine

    (1991)
  • GabrielSE et al.

    The cost-effectiveness of misoprostol for nonsteroidal antiinflammatory drug-associated adverse gastrointestinal events

    Arthritis and Rheumatism

    (1993)
  • GabrielSE et al.

    Costs of osteoarthritis: Estimates from a geographically defined population

    Journal of Rheumatology

    (1995)
  • GabrielSE et al.

    Indirect and non-medical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls

    Journal of Rheumatology

    (1997)
  • Cited by (260)

    • The Burden of Osteoarthritis in Older Adults

      2022, Clinics in Geriatric Medicine
      Citation Excerpt :

      Greater pain catastrophizing, poor coping, and lower social support have consistently been found to negatively influence the impact of OA pain on sleep, fatigue, disability, and mood, and thus on OA-related quality of life over time.9,10,12 Musculoskeletal conditions, including OA, have a substantial contribution to health care costs, accounting for an estimated 1.0% to 2.5% of the gross domestic product in the United States, Canada, the United Kingdom, France, and Australia.64 Approximately 80% of the costs owing to musculoskeletal conditions are estimated to be related to symptomatic OA, including direct costs to the health care system, indirect costs to individuals living with OA, and the intangible costs of living with a chronic disabling condition (Table 1).65

    • The burden of OA-health services and economics

      2022, Osteoarthritis and Cartilage
      Citation Excerpt :

      Years in which costs were originally reported are noted. The direct costs of OA amount to 1–2.5% of Gross National Product in countries with established market economies such as the US, UK, Canada, and Australia55. In 2013 in the US, OA was the second most costly medical condition treated in US hospitals, accounting for 4.3% ($18.4 billion) of all hospitalization costs ($415 billion)56.

    View all citing articles on Scopus
    View full text